CORT vs PAHC

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus 12. 8% for Corcept Therapeutics Incorporated (CORT). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus Corcept Therapeutics Incorporated at 62. 3x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x.

Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +141.

9%, compared to +66. 0% for Phibro Animal Health Corporation (PAHC). Over 10 years, the gap is even starker: CORT returned +929. 2% versus PAHC's +128. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Phibro Animal Health Corporation (PAHC) is the lower-risk stock at 1.

38β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 29% more volatile than PAHC relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus 12. 8% for Corcept Therapeutics Incorporated (CORT). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -33. 3% for Corcept Therapeutics Incorporated. Over a 3-year CAGR, CORT leads at 23. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.

1% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 13. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus 5. 9% for CORT. At the gross margin level — before operating expenses — CORT leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14.

2x forward P/E versus 136. 0x for Corcept Therapeutics Incorporated — 121. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 40. 4% to $71. 67.

In this comparison, PAHC (1.

1% yield) pays a dividend. CORT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +128. 6% 10Y return). Corcept Therapeutics Incorporated (CORT) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAHC: +128. 6%, CORT: +929. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CORT is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock. PAHC pays a dividend while CORT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.